Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05702476

Marfan Syndrome (MFS) and Facial Dysmorphism: Non-invasive 3D Assessment

The goal of this study observational prospective study is to define the facial morphological features associated with Marfan syndrome (MFS). The main qustion it aims to answer are:

1. To describe the facial morphological features associated with MFS and their evolution over time; 2. To study the association between facial morphology and the features of reference for the diagnosis of MFS.

Recruiting

Interested in participating?

Request Info

Key information

About this study

Marfan syndrome (MFS, OMIM # 154700) is a rare connective tissue disorder caused by mutations in the gene encoding fibrillin-1 glycoprotein (FBN1), involved in the development of microfibrils. Since FBN1 is a constituent of the connective tissue present at a systemic level, mutations in its gene lead to alterations of the connective tissue, even with pleiotropic effects. The clinical manifestations of MFS are heterogeneous and can occur at any time, from neonatal onset to infancy or adolescence. In this sense, the presence of facial dysmorphism could help in early diagnosis of the disease. Considering the craniofacial features, the phenotypic manifestation related to the syndrome MFS are: dolichocephaly, eyelid down-slanting, malar hypoplasia and retrognathia. However, Few studies have so far studied the facial features associated with MFS. Morevoer, there is a gap in the literature for the evaluation of the progression of facial morphology in the pediatric MFS population as well as potential correlations between facial dysmorphism and other manifestations of the disease.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • White european ethnicity;
  • Signed informed consent;

Exclusion criteria

  • Previous relevant traumas affecting the craniofacial district or maxillofacial surgery;
  • Presence of beard and mustache;
  • Pregnancy

Treatment and study plan

Primary outcomes

  1. Disease Progression

    Time frame: 18 months

    Prospective evaluation focused in the craniofacial area in MFS patients

Study contacts

Contact information is provided by the study sponsor or research team.

Alessandro Pini, MD

CONTACT

[email protected]

+390252774705

Sponsors and collaborators

Lead sponsor

IRCCS Policlinico S. Donato

Other

Collaborators

  • University of Milan

Registry information

Acronym: FACE

Important dates

Study start
2023
Primary completion
2026
Study completion
2027
First posted
Jan 27, 2023
Registry last updated
Jan 13, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.